{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:12:26Z","timestamp":1791850346510,"version":"4.3.4"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,2,26]],"date-time":"2013-02-26T00:00:00Z","timestamp":1361836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Care &amp;amp; Research"],"published-print":{"date-parts":[[2013,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine the \u201creal\u2010world\u201d clinical effectiveness and safety of leflunomide in patients with psoriatic arthritis (PsA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This prospective, multinational 24\u2010week observational study involved adult patients with active PsA who initiated treatment with leflunomide. Patients were evaluated at baseline, 12 weeks, and 24 weeks. The primary outcome was response as assessed by the Psoriatic Arthritis Response Criteria (PsARC) in patients with pre\u2010 and posttreatment data. A modified PsARC response analysis included patients with joint counts, but no severity scores. Other effectiveness evaluations included global assessments, fatigue, pain, skin disease, dactylitis, and nail lesions. All patients were evaluated for safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 514 patients were enrolled in this study (mean age 50.7 years, mean disease duration 6.1 years). In the primary effectiveness analysis, 380 (86.4%) of 440 patients (95% confidence interval 82.8%\u201389.4%) achieved a PsARC response at 24 weeks. Significant improvements were observed in tender and swollen joint scores and counts, patient and physician global assessments, fatigue, pain, skin disease, dactylitis, and nail lesions. The discontinuation rate was 12.3%. Ninety\u2010eight adverse drug reactions occurred in 62 (12.1%) patients; 3 drug reactions were serious (2 increased liver enzymes, 1 hypertensive crisis).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Leflunomide is an effective and well\u2010tolerated option for PsA in daily clinical practice, with beneficial effects on peripheral arthritis and on other PsA manifestations, including pain, fatigue, dactylitis, and skin disease.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.21848","type":"journal-article","created":{"date-parts":[[2012,10,6]],"date-time":"2012-10-06T11:33:09Z","timestamp":1349523189000},"page":"464-470","source":"Crossref","is-referenced-by-count":67,"title":["Leflunomide in psoriatic arthritis: Results from a large European prospective observational study"],"prefix":"10.1002","volume":"65","author":[{"given":"Frank","family":"Behrens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Finkenwirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Pavelka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"S\u0306tolfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alenka","family":"S\u0306ipek\u2010Dolnicar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Burkhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,2,26]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/23.4.246"},{"key":"e_1_2_8_3_2","first-page":"2577","article-title":"Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritis questionnaire","volume":"29","author":"Alenius GM","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.029207"},{"key":"e_1_2_8_5_2","first-page":"1918","article-title":"Prevalence, disease manifestations, and treatment of psoriatic arthritis in Western Norway","volume":"32","author":"Madland TM","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_8_6_2","first-page":"S652","article-title":"Comparative study of MR imaging findings in wrist and hands in early psoriatic arthritis and rheumatoid arthritis","volume":"56","author":"Narvaez J","year":"2007","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_7_2","first-page":"1842","article-title":"Comparison of disability and quality of life in rheumatoid and psoriatic arthritis","volume":"28","author":"Sokoll KB","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_8_8_2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T","article-title":"Health\u2010related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis","volume":"45","author":"Husted JA","year":"2001","journal-title":"Arthritis Care Res"},{"key":"e_1_2_8_9_2","first-page":"86","article-title":"Healthcare and burden of disease in psoriatic arthritis: a comparison with rheumatoid arthritis and ankylosing spondylitis","volume":"33","author":"Zink A","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_8_10_2","unstructured":"European Medicines Agency. Leflunomide summary of product characteristics.2010. URL:http:\/\/www.ema.europa.eu\/humandocs\/Humans\/EPAR\/arava\/arava.htm."},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20253"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000091251"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780391210"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-4475-7"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.58.2008.i82"},{"key":"e_1_2_8_16_2","first-page":"472","article-title":"Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs: comparison of drugs and adverse reactions","volume":"35","author":"Helliwell PS","year":"2008","journal-title":"J Rheumatol"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes001"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei153"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.064808"},{"key":"e_1_2_8_20_2","first-page":"1167","article-title":"Consensus on a core set of domains for psoriatic arthritis","volume":"34","author":"Gladman DD","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.057901"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.018184"},{"key":"e_1_2_8_23_2","first-page":"1439","article-title":"Therapies for dactylitis in psoriatic arthritis: a systematic review","volume":"33","author":"Helliwell PS","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_8_24_2","first-page":"1422","article-title":"Therapies for peripheral joint disease in psoriatic arthritis: a systematic review","volume":"33","author":"Soriano ES","year":"2006","journal-title":"J Rheumatol"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.21848","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.21848","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T17:16:18Z","timestamp":1759425378000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.21848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,26]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.1002\/acr.21848"],"URL":"https:\/\/doi.org\/10.1002\/acr.21848","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,26]]}}}